Analysis of the CYP3A4*1B Gene Variant in an Iranian Population: Pilot Base Study

Karimpur Zahmatkesh, Arezu; Movafagh, Abolfazl

doi:10.18052/www.scipress.com/IJPPE.1.5

IJPPE > IJPPE Volume 1 > Analysis of the CYP3A4*1B Gene Variant in an...

< Back to Volume

Analysis of the CYP3A4*1B Gene Variant in an Iranian Population: Pilot Base Study

Full Text PDF

Abstract:

Various studies revealed that, CYP3A4*1B, as a variant allele of CYP3A4 gene, has variations in populations with different ethnic background. In this pilot research work, we studied 183 healthy non consanguinity men of an Iranian origin for this genetic variation. We applied RFLP-PCR technique for this research study. In contrast with other researches, in Asian country (such as China and Japan with 0% allele frequency) our study showed that frequency of this allele in Iranian men among an Asian continent is 3%. This finding is an important attempt in pharmacogenetics research endeavor.

Info:

Periodical:

International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 1)

Pages:

5-9

DOI:

https://doi.org/10.18052/www.scipress.com/IJPPE.1.5

Citation:

A. Karimpur Zahmatkesh and A. Movafagh, "Analysis of the CYP3A4*1B Gene Variant in an Iranian Population: Pilot Base Study", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 1, pp. 5-9, 2015

Online since:

December 2015

Authors:

Arezu Karimpur Zahmatkesh, Abolfazl Movafagh

Keywords:

CYP3A4, CYP3A4 1B, CYP450, Genetic Variant

Export:

RIS, BibTeX, Text

Distribution:

Open Access

This work is licensed under a
Creative Commons Attribution 4.0 International License

References:

Eichelbaum, M., M. Ingelman-Sundberg, and W.E. Evans, Pharmacogenomics and individualized drug therapy. Annu. Rev. Med.,. 5 7: pp.119-137 (2006).

Hu, Y.F., et al., CYP3A5* 3 and CYP3A4* 18 single nucleotide polymorphisms in a Chinese population. Clinica chimica acta,. 3 5 3(1): pp.187-192(2005).

Lamba, J.K., et al., Genetic contribution to variable human CYP3A-mediated metabolism. Advanced drug delivery reviews,. 5 4(10): pp.1271-1294(2002).

Shih, P.S. and J.D. Huang, Pharmacokinetics of midazolam and 1-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug metabolism and disposition,. 3 0(12): pp.1491-1496(2002).

Keshava, C., E.C. McCanlies, and A. Weston, CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. American journal of epidemiology, 1 6 0(9): pp.825-841(2004).

Bork, R., et al., Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. Journal of Biological Chemistry, 2 6 4(2): pp.910-919(1989).

Beaune, P.H., et al., Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proceedings of the National Academy of Sciences, 8 3(21): p.8064(1989).

Linder, M.W., R.A. Prough, and R. Valdes Jr, Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clinical Chemistry,. 4 3(2): pp.254-266(1997).

Hashimoto, H., et al., Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. European Journal of Biochemistry, 2 1 8(2): pp.585-595(1993).

Rebbeck, T.R., et al., Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Journal of the National Cancer Institute, 9 0(16): p.12251229(1998).

Amirimani, B., et al., Increased transcriptional activity of the CYP3A4* 1B promoter variant. Environmental and molecular mutagenesis, 4 2(4): pp.299-305(2003).

Felix, C.A., et al., Association of CYP3A4 genotype with treatment-related leukemia. Proceedings of the National Academy of Sciences, 9 5(22): p.13176(1998).

von Moltke, L.L., et al., Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region. The Journal of Clinical Pharmacology, 4 0(2): pp.200-204(2000).

Sata, F., et al., CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clinical Pharmacology & Therapeutics, 6 7(1): pp.48-56(2000).

Ball, S.E., et al., Population distribution and effects on drug metabolism of a genetic variant in the 5 promotor region of CYP3A4. Clinical Pharmacology & Therapeutics, 6 6(3): p.288294 (1999).

Cavalli, S.A., M.H. Hirata, and R.D.C. Hirata, Detection of MboII polymorphism at the 5 promoter region of CYP3A4. Clinical chemistry, 4 7(2): pp.348-351(2001).

Arvanitidis, K., et al., Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundamental & clinical pharmacology, 2 1(4): pp.419-426 (2007).

Miao, J., et al., Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. The pharmacogenomics journal, 9(5): pp.319-326(2009).

Oliveira, E., et al., Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics, 8(7): pp.703-712(2007).

Wolbold, R., et al., Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 38(4): pp.978-988(2003).

Show More Hide

Cited By:

This article has no citations.